skip to Main Content

Clinical Trial for Children with Autism and Anxiety

Autism Spectrum Disorder (ASD) currently affects about 2% of children. One of the most problematic issues in adolescents and adults with ASD is anxiety. Anxiety can be debilitating. In high-functioning individuals with ASD, anxiety commonly results in a reluctance to engage in social activities as well as interferes with the ability to perform academically. At the Phoenix Children`s Hospital, Division of Neurodevelopmental Disorders we are studying Transcutaneous Electrical Neurostimulation (TENS), a treatment that painlessly stimulates cranial nerves to modulate brain circuits involved in anxiety. Similar devices are already FDA approved for the treatment of migraines and ADHD.

In a one-week controlled clinical trial we are studying the safety and efficacy of TENS to improve both anxiety and sleep in adolescents and adults aged 10-25 years with normal intelligence. We would be appreciative of any referrals of potential participants.

If you are interested in learning more about the study or have any questions, please contact Amanda Jensen at 602-933-2979 or ajensen1@phoenixchildrens.com or Dr. Richard Frye, Chief of Neurodevelopmental disorders, the Principal Investigator of this study.

Click here for program flyer

Clinical Trial for Children with Autism and Language Impairment

Autism Spectrum Disorder (ASD) current affects about 2% of children. One of the most problematic issues in children with ASD is language impairment. At Phoenix Children`s Hospital, Division of Neurodevelopmental Disorders we are studying the safety and effectiveness of Leucovorin for Language Impairment in Children with ASD ages 2 1/2 to 12 years old in several federally funded FDA approved randomized controlled clinical trials.

These research studies are based on published evidence suggesting that leucovorin, a reduced form of folate, can circumvent a blockage in folate metabolism commonly found in children with ASD.  These studies are placebo controlled and have two 12-week phases. In the first phase of the study, some children will receive leucovorin and others will receive placebo. The second phase of the trial is open-label, meaning that all participants will receive leucovorin.

We would be appreciative of any referrals of potential participants. If you are interested in learning more about the study or have any questions, please contact Sallie McLees at (602) 933-0964 or smclees@phoenixchildrens.com or Dr. Richard Frye, Chief of Neurodevelopmental disorders, the Principal Investigator of this study.

Click here for program flyer

Back To Top